查看文章

Background: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in patients with endometrial cancer with respect to response, progression-free survival (PFS) and overall survival (OS).

Patients and methods: Eligible chemotherapy-naïve patients were randomly assigned to doxorubicin 60 mg/m² intravenously (i.v.) followed by cisplatin 50 mg/m² i.v. (arm 1, n=157) or doxorubicin 50 mg/m² i.v. followed 4 h later by paclitaxel 150 mg/m² i.v. over 24 h plus filgrastim 5 μg/kg on days 3–12 (arm 2, n=160). Starting doses were reduced for prior pelvic radiotherapy and age >65 years. Both regimens were to be repeated every 3 weeks for a maximum of seven cycles.

Results: There was no significant difference in response rate (40% versus 43%), PFS (median 7.2 versus 6 months) or OS (median 12.6 versus 13.6 months) for arm 1 …